• About Us
  • Paper Locations
  • Contact
Wednesday, May 25, 2022
MEDIA KIT
African American News and Issues
63 °f
Houston
  • National
  • Local
  • Opinion
  • Sports
  • Education
  • Health
  • Politics
  • Announcements
  • Videos
  • Events
  • Entertainment
No Result
View All Result
African American News and Issues
  • National
  • Local
  • Opinion
  • Sports
  • Education
  • Health
  • Politics
  • Announcements
  • Videos
  • Events
  • Entertainment
No Result
View All Result
African American News and Issues
No Result
View All Result
Home COVID-19

Moderna vaccine appears to offer strongest protection against COVID

aframnews by aframnews
8 months ago
in COVID-19, Health, News, NNPA Coronavirus Task Force
0
Moderna vaccine appears to offer strongest protection against COVID
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter
FacebookTwitterPinterestLinkedIn

According to a new report from the Centers for Disease Control and Prevention, two-dose regimens of the Moderna and Pfizer-BioNTech mRNA vaccines provided a high level of protection against COVID-19 hospitalizations in a real-world evaluation at 21 U.S. hospitals during the period between March 11 and August 15.

You might also like

With Inpatient Psychiatric Services in Short Supply, America’s Teen Mental Health Emergency Deepens

Older African Americans Experience Discrimination From Healthcare Providers

America’s Teens in Crisis: Mental Health Disorders Now Biggest Concern

Vaccine effectiveness against COVID-19 hospitalization for Moderna and Pfizer-BioNTech doses were 93 percent and 88 percent, respectively, whereas the single-dose Janssen [Johnson & Johnson] vaccine had a lower effectiveness rate at 71 percent.

Protection for the Pfizer-BioNTech vaccine declined four months after vaccination.

Released Friday, September 17, the report revealed that individuals vaccinated with the Janssen vaccine also had lower post-vaccination anti-SARS-CoV-2 antibody levels than did recipients of mRNA vaccines.
In addition, although an immunologic correlate of protection has not been established for COVID-19 vaccines, the researchers found that antibody titers after infection and vaccination have been associated with protection.

“These real-world data suggest that the 2-dose Moderna and Pfizer-BioNTech mRNA vaccine regimens provide more protection than does the 1-dose Janssen viral vector vaccine regimen,” the researchers wrote.

“Although the Janssen vaccine had lower observed vaccine effectiveness, one dose of Janssen vaccine still reduced risk for COVID-19–associated hospitalization by 71 percent.”
The study included 3,689 patients.

Overall, 2,362 (64 percent) were unvaccinated; 476 (12.9 percent) were fully vaccinated with the Moderna vaccine; 738 (20 percent) were fully vaccinated with the Pfizer-BioNTech vaccine, and 113 (3.1 percent) were fully vaccinated with the Janssen vaccine.

Among all participants, the median age was 58 years, 48 percent female, 23 percent non-Hispanic Black, and 18 percent Hispanic.

Efficacy for the Moderna vaccine was 93 percent at 14 to 120 days (the median equaled 66 days) after receiving the second vaccine dose and 92 percent after 120 days (with the median equaling 141 days).
For Pfizer-BioNTech, efficacy stood at 91 percent at 14 to 120 days (the median equaled 69 days) after receiving the second vaccine dose but declined significantly to 77 percent at more than 120 days (the median equaled 143 days).

The postvaccination antibody analysis included 100 healthy volunteers, 32 fully vaccinated with Moderna, 51 fully vaccinated with Pfizer-BioNTech, and 17 with Janssen.

Antibody levels were higher in participants vaccinated with the Moderna vaccine than those who received the Pfizer-BioNTech vaccine or the Janssen vaccine.

The report revealed that anti-spike levels in participants vaccinated with the Moderna vaccine did not significantly differ from those in recipients of the Pfizer-BioNTech but were considerably higher than levels in participants who received the Janssen.

The report arrives as a U.S. Food and Drug Administration panel reviewed the need for booster shots of the Pfizer-BioNTech coronavirus vaccine.

The panel also expected to vote on whether the agency should approve additional doses for people 16 and older.

“We will evaluate and see,” said Dr. James Hildreth, the president and CEO of Meharry Medical College and an FDA panelist deciding on the booster shots.

Tags: antibody levelsBioNTechCOVID-19effectivenessFDAhospitalizationsJannsenJohnson & Johnsonmeharry medical collegeModernaPfizerReportSARS-CoV-2 vaccines
Share30Tweet19
aframnews

aframnews

Recommended For You

With Inpatient Psychiatric Services in Short Supply, America’s Teen Mental Health Emergency Deepens

by Chelsea Davis-Bibb
8 months ago
0
With Inpatient Psychiatric Services in Short Supply, America’s Teen Mental Health Emergency Deepens

With inpatient psychiatric services reportedly in short supply, teenagers aren’t receiving the care they need. By Stacy M. Brown NNPA Newswire Senior National Correspondent @StacyBrownMedia According to the...

Read more

Older African Americans Experience Discrimination From Healthcare Providers

by aframnews
8 months ago
0

By: Jennifer Magdalene One in four older Black Americans have felt discriminated against by doctors and healthcare professionals who’ve either treated them unfairly or ignored their concerns, a...

Read more

America’s Teens in Crisis: Mental Health Disorders Now Biggest Concern

by Chelsea Davis-Bibb
8 months ago
0
America’s Teens in Crisis: Mental Health Disorders Now Biggest Concern

By Stacy M. Brown NNPA Newswire Senior National Correspondent @StacyBrownMedia Mental health disorders stand as a chief concern among American teenagers, according to researchers who said the pervasiveness...

Read more

Judge Jackson’s Supreme Court hearings set as support grows for confirmation

by aframnews
8 months ago
0
Judge Jackson’s Supreme Court hearings set as support grows for confirmation

The Senate Judiciary Committee will begin its confirmation hearings to determine whether President Joe Biden’s Supreme Court nominee Ketanji Brown Jackson will make history as the first Black...

Read more

Has The Black Press Lost Its Way?

by aframnews
8 months ago
0
Has The Black Press Lost Its Way?

By: Roy Douglas Malonson When you think about the purpose of the “black press,” what comes to mind? This is a question that is not asked enough. Journalism...

Read more
Next Post
Rep. Beatty introduces legislation to establish National Rosa Parks Day

Rep. Beatty introduces legislation to establish National Rosa Parks Day

Latest Articles

The Obama Portraits Tour

The Obama Portraits Tour

8 months ago
With Inpatient Psychiatric Services in Short Supply, America’s Teen Mental Health Emergency Deepens

With Inpatient Psychiatric Services in Short Supply, America’s Teen Mental Health Emergency Deepens

8 months ago
Supreme Court Decision Heavily Diminishes Ineffective Counsel Defense

Supreme Court Decision Heavily Diminishes Ineffective Counsel Defense

8 months ago

NEED PAST ISSUES?

Search our archive of past issues Receive our Latest Updates
* indicates required
  • Local
  • National
  • Community
  • Education
  • Politics
  • COVID-19
  • Entertainment
  • Lifestyle
  • Sports

ARTICLES

  • Local
  • National
  • Community
  • Education
  • Politics
  • COVID-19
  • Entertainment
  • Lifestyle
  • Sports

CONNECT WITH US

  • Home
  • Advertise With Us
  • Contact
African American News and Issues

African American News & Issues
6130 Wheatley St
Houston, TX 77091
(713) 692-1892

Subscribe To Our Newsletter

Copyright © 2022. African American News & Issues. All rights reserved. Private Policy | Terms of Use |

No Result
View All Result
  • Home
  • National
  • Local
  • Opinion
  • Sports
  • Education
  • Health
  • Politics
  • Entertainment
  • Announcements
  • Events
  • Videos
  • Contact

Copyright © 2022. African American News & Issues. All rights reserved. Private Policy | Terms of Use |

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?